MedElevator
Войти в исследования Annals of clinical and laboratory science · 2026
Myeloid Neoplasm with Eosinophilia Harboring a Novel CCDC6::PDGFRB fusion: Diagnostic Challenge and Therapeutic Implications.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ovechko Vasily, Ghosh Anindita, Garces Sofia, Tang Guilin, Yin C Cameron
Аннотация
OBJECTIVE: Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions are rare hematologic malignancies characterized by constitutive kinase activation and sensitivity to tyrosine kinase inhibitors. PDGFRB rearrangements are uncommon, and CCDC6::PDGFRB fusion has been reported only rarely.
CASE REPORT: A 44-year-old man presented with leukocytosis, eosinophilia, anemia, splenomegaly, and constitutional symptoms. A bone marrow examination showed granulocytic hyperplasia with marked eosinophilia. Cytogenetic analysis revealed t(5;10)(q32;q21), while optical genome mapping identified a CCDC6::PDGFRB fusion, confirmed by fluorescence in situ hybridization. No additional pathogenic mutations were detected by targeted next-generation sequencing. Treatment with low-dose imatinib achieved rapid hematologic remission, which was maintained at 22 months.
CONCLUSIONS: This case highlights the importance of comprehensive genomic testing in patients with eosinophilia-associated myeloid neoplasms for identifying rare and therapeutically actionable PDGFRB rearrangements.
CASE REPORT: A 44-year-old man presented with leukocytosis, eosinophilia, anemia, splenomegaly, and constitutional symptoms. A bone marrow examination showed granulocytic hyperplasia with marked eosinophilia. Cytogenetic analysis revealed t(5;10)(q32;q21), while optical genome mapping identified a CCDC6::PDGFRB fusion, confirmed by fluorescence in situ hybridization. No additional pathogenic mutations were detected by targeted next-generation sequencing. Treatment with low-dose imatinib achieved rapid hematologic remission, which was maintained at 22 months.
CONCLUSIONS: This case highlights the importance of comprehensive genomic testing in patients with eosinophilia-associated myeloid neoplasms for identifying rare and therapeutically actionable PDGFRB rearrangements.